The EMA held a symposium on 29 October to discuss the potential use of input from cancer patients in informing medicine development and regulatory decision-making.
The symposium was hosted virtually due to the COVID-19 pandemic. It was broadcasted live on the event page, and a video recording will be published afterwards. The event’s agenda has also been released.
The aim of the symposium is to generate recommendations that will increase patient contribution and involvement in the data collection, development and evaluation of cancer medicines. This will provide concrete steps to help the EMA improve the development and regulation of cancer treatments.
Guido Rasi, Executive Director of the EMA, said:
“Involving cancer patients in the regulatory process is important because they can provide critical input based on their real-life experiences with the disease and its treatment. Their contributions are deeply embedded in the scientific work and regulatory output of EMA.”